Member Info for Moab

I cannot think of a single reason why AFC should have gone to the trouble and expense of doing this. Bond is long gone, and there was no need for this somewhat paranoid change of name.

Thanks for excellent summary

Lazy

EXITING or EXCITING! Small difference here.

Carrot

All alone in yr echo chamber. 9 posts since 4th March, but sadly the only poster in that time. You must be very lonely. My sympathies.

As PHE seems dead in the water I can understand why posters are discussing anything else but PHE. Not even a rant from Swazers!

Carrot

" Parsortix can catch these for very detailed analysis. Very detailed. Therefore, I submit that Grail would benefit from adding CTC analysis to their tests. "

No.

The purpose of the Grail trial was to REDUCE the proportion of patients presenting with stage 3-4 tumours. I cannot see the proportion / number of tumours that presented in stage 3-4, but would guess it to be signifianctly smaller than stage 1-2, because in the whole population many stage 3-4 will have generally presented with symptoms already. So one would be using Parsortix (not cheap in materials or manpower) to help with the assessment of a minority of patients. Far better and financially more sensible to limit use of Parsortix to patients already found to have fragments of DNA washing around in plasma. Even in this group, I doubt if Parsortix has a routine place in EARLY evaluation of tumour site.

At present I can only see Parsortix being of value in examining tumour expression as a guide to targeted drug treatment. The Galleri study had an entirely different purpose.

Carrot

Yes

Carrot

"My point is Grail would benefit from using so called "dual analysis" because it would make the analysis far better."

Why? The purpose of the study was to examine whether Galleri could REDUCE the number of stage 3-4 presentations by earlier diagnosis. The overall study did not show a significant difference between control and investigated groups, so some intensive post hoc (unspecified in the original protocol) data dredging has now gone on to find some crumbs of comfort for Grail. I cannot see how the addition of Parsortix, on the off chance that it might show up CTCs in the whole of the investigated Galleri population would be cost effective or worthwhile.

Carrot

The answer to your headline question is that Parsortix will not help with EARLY cancer detection, that is stage 1-2, before extracapsular spread, or spread to adjacent lymph nodes has taken place. Adding Parsortix to the trial will not alter EARLY detection rates. and so I do not think Parsortix can add anything to the intention of Grail to pick up ealy cancers.

As for CTC detection in stage 3-4 tumours, the answer is, and always has been, yes, of course they MAY be detected. But my position is that it is not a given that CTCs will be found in late stage cancers,

Carrot

For FFS stop this nonsense even if you were the only person to look at your posts.

"GRAIL, Inc. is a healthcare company focused on early cancer detection, aiming to reduce cancer mortality through its multi-cancer early detection (MCED) technology. They developed Galleri, a blood test that uses next-generation sequencing and machine learning to detect multiple types of cancer at early stages, particularly for asymptomatic individuals over age 50. "

Parsortix MAY provide circulating tumour cells in patients in whom metastasis is taking place. This means, if I can explain for the umpteenth time, that a) the tumour is already mature enough to metastasise, and b) this cannot be, even by any stretch of your fevered imagination, be thought of as "early cancer detection"

The answer to your headline question is It cannot help with EARLY cancer detection.

MudPump

Performance good, and the only one of its kind. but only isolates tumour cells when there is metastasis, with circulating tumour cells. So even in presence of known mets, isolating tumour cells from blood is not a given. So it is not 100% guaranteed to produce cells for analysis, and from memory it may be as low as 66% in one study.

I cannot comment on bad actors, but I don't doubt that someone would be making money out of the Parsortix process, including any physician that ordered it. Unfortunately not Angle. There have been trials galore, looking at tumour other than breast, including brain and prostate, but no one has yet found it sufficiently useful in clinical practice. The possibility of a link up with the likes of Illumina , who look at tumour DNA fragments in whole blood, presently remains a possibilty, but presently things are quiet on that front.

One can only hope that the present management does better than Newland et al.

The fundamental problem here goes back a year or 3. For whatever reason Parsortix did not take off in the US, or anywhere else, as a clinical tool after FDA approval. The dream was a machine in every cancer centre, with a large population of patients needing assessment of their breast tumour type. Instead it has had to scratch around providing data for pharma, and is at thus the mercy of pharma research programmes. Relatively small volumes being involved.

It will be interesting to see what the new man comes up with as a strategy, given these limitations. Parsortix can, of course , be used in the typing of all and any tumours, but I do not see this getting back into clinical use as opposed to research anytime soon. Breath holding not recommended.

Carrot

A predictable distraction from the significant RNS news of the day.

H-J

Nitrogen already constitutes ~78% of the atmosphere; why should N2 emissions from NH3 breakdown be a concern?. It is pretty inert and in any event NH3 is made from atmospheric nitrogen in the first place; this is just recycling. it I would be a tad more worried about rising CO2.

Carot

Some info for your echo chamber.

TXA2 inhibiting dose is v small ~75mg day, so risk of GI bleeding is small, and outweighed by potential advantage of keeping platelets from aggregating on CTCs. Risk of intracerebral bleeds increases with age >75 or so.

(not AI generated)

It is all gobblydegook; stick to chicken entrails.

Carrot

Back again I see, we missed your ramps for a few days; quite peaceful.

And 4 days without a post from Carrot; things are really bad.

By when will the inevitable fund raise be needed? Any views?

Westy

Cost per molecule? I am guessing, but 0.0000000000000000000000000000000000000001p might cover it.